Sulfonylurea Therapy in Two Korean Patients with Insulin-treated Neonatal Diabetes due to Heterozygous Mutations of the KCNJ11 Gene Encoding Kir6.2 by Kim, Min Sun et al.
INTRODUCTION
Neonatal diabetes, defined as insulin-requiring hypergly-
cemia within the first three months of life, is a rare disease
entity, with an estimated incidence of 1 in 400,000 neonates
(1). Transient neonatal diabetes usually resolves by a median
of 12 weeks and is generally associated with an abnormality
of the imprinted region of 6q24 (2). By contrast, permanent
neonatal diabetes (PND) requires insulin treatment for life,
and until recently the genetic etiology was largely unknown.
Recently, Gloyn et al. (3) reported that heterozygous activat-
ing mutations in the KCNJ11 gene are a common cause of
PND. KCNJ11 encodes Kir6.2, the pore-forming subunit
of the ATP-sensitive K
+ channel (KATP channel) (4). KATP
channels play a central role in glucose-stimulated insulin
secretion from pancreatic  -cells (5). 
Sulfonylurea stimulates insulin secretion by binding to the
-cell’s high-affinity sulfonylurea receptor and closing the
ATP-sensitive K+ channels by an ATP-independent mech-
anism (6). Sagen et al. (7) recently reported that oral sulfo-
nylurea should be considered for treatment of patients with
Kir6.2 mutations. 
We report the first two Korean cases of PND with muta-
tions in the KCNJ11 gene encoding Kir6.2. In addition, we
also show that oral sulfonylurea therapy is as good as or bet-
ter for glycemic control, compared with insulin therapy.
MATERIALS AND METHODS
Two Korean children with permanent neonatal diabetes
were evaluated. Neither the parents nor their siblings had
diabetes. The mothers did not have gestational diabetes.
Written informed consent was obtained from the parents
for study participation and publication. 
Case 1 
Case 1, born at 40 weeks gestation, was well at birth but
had intrauterine growth retardation with a birth weight of
2,300 g (<3 percentile). She was the first child of two sib-
lings. At six weeks of age, diabetes was diagnosed based on
hyperglycemia (1,460 mg/dL) and glucosuria (3+) with keto-
acidosis. The serum C-peptide was 0.4 ng/mL (normal range:
1.0-3.5) and HbA1C was 6.9% (normal range, 2.1-7.7). Au-
toantibodies associated with type 1 diabetes and pancreatic
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Sulfonylurea Therapy in Two Korean Patients with Insulin-treated
Neonatal Diabetes due to Heterozygous Mutations of the KCNJ11
Gene Encoding Kir6.2
Permanent neonatal diabetes (PND) is a rare form of diabetes characterized by
insulin-requiring hyperglycemia diagnosed within the first three months of life. In
most cases, the causes are not known. Recently, mutations in the KCNJ11 gene
encoding the Kir6.2 subunit of the ATP-sensitive K
+ channel have been described
in patients with PND. We report the first two Korean cases with PND due to a lysine-
to-arginine substitution at position 170 (K179R) and a valine-to-methionine substi-
tution at position 59 (V59M) mutations of KCNJ11 encoding Kir6.2, respectively.
After several years of insulin therapy, these patients were managed by oral gliben-
clamide therapy at a daily dose of 0.8-0.9 mg/kg. Their basal c-peptide levels in-
creased after one week of glibenclamide therapy, and one month later, the insulin
and c-peptide levels were in the normal ranges without any episodes of hyper- or
hypoglycemia. These cases demonstrate that oral sulfonylurea may be the treat-
ment of choice in PND patients with KCNJ11 mutations even at a young age. 
Key Words : Neonatal Diabetes; Permanent; Korean; Sulfonylurea; Kir6.2 Channel; Mutation
Received : 5 December 2006
Accepted : 12 January 2007Sulfonylurea Therapy for Permanent Neonatal Diabetes  617
ultrasonography were negative. The patient did not have
dysmorphic features. Insulin therapy was initiated and insulin
doses of 0.6-0.8 units/kg/day were required. There was marked
catch-up growth after birth, and the weight and height were
normally distributed on follow-up after 6.5 yr.
Psychomotor development and muscle strength were with-
in normal limits. We recently introduced oral sulfonylurea
to the patient. We started with glibenclamide at a dose of
0.2 mg/kg/day, consisting of four doses a day and increased
the doses up to 0.9 mg/kg/day over eight days. One month
later, the glibenclamide dose was 7.5 mg three times a day.
Case 2
This patient was born after 37 weeks gestation by cesare-
an section delivery with a birth weight of 3,000 g (10-25
percentile). He was the second child of two siblings. At six
weeks of age, diabetes was diagnosed based on hyperglycemia
(>500 mg/dL) and glucosuria (3+) with ketoacidosis. Auto-
antibodies associated with type 1 diabetes were not present,
and the pancreatic ultrasonography was negative. Insulin
therapy was initiated and the average daily insulin dose before
sulfonylurea therapy was 0.6 units per kg. 
The patient is now 3.8 yr of age, and his weight is 13.5 kg
(3-10 percentile), and height is 100.0 cm (50-75 percentile),
and the head circumference is 51.0 cm (50-75 percentile).
The serum C-peptide was 0.08 ng/mL, and HbA1C was 8.7%.
There were no dysmorphic features. However, he had mod-
erate motor and mental developmental delay. He also had
muscle weakness in both extremities. He did not have epilep-
sy, and the electroencephalogram was normal limits. At the
age of 3.8 yr, he was admitted for a trial of glibenclamide
therapy. The insulin therapy was discontinued over two days,
and glinbenclamide was given with an initial dose of 0.05
mg/kg four times a day, and the dose was increased up to
0.9 mg/kg/day. 
Molecular genetic analysis
Genomic DNA was isolated from peripheral blood using
a PUREGENE DNA isolation kit (Gentra, Minneapolis,
MN, U.S.A.). Five exons of the KCNJ11 gene and their in-
tronic flanking sequences were amplified by polymerase chain
reaction (PCR) with five sets of primers (Table 1). Electro-
phoresis and analysis of the reaction mixtures were performed
on the ABI 3100 Genetic analyzer (Applied Biosystems,
Foster city, CA, U.S.A.).
Continuous glucose monitoring system 
Continuous glucose monitoring was performed using on
the continuous glucose monitoring system (CGMS, Med-
tronic MiniMed, Sylmar, CA, U.S.A.) three times in case 1:
at the initiation of glibenclamide therapy, one week and one
month later after glinbenclamide therapy. CGMS is a Holter-
style sensor that monitors glucose values continuously in sub-
Sense (5′ -to-3′ ) Antisense (5′ -to-3′ )
Exon 1 gtctggtggggagttatctcag gtgaagatgagcaatgtgtgtg
Exon 2 tttgtgtccaagaaaggcaact gatgttctgcacgatgaggat
Exon 3 ttttctccattgaggtccaagt cgttctccatggggatgtc
Exon 4 catgatcatcagcgccac agtccacagagtaacgtccgtc
Exon 5 acctcctacctggccgatga ctggcccagcctcacaccag
Table 1. Sequences of primers for PCR reaction
PCR, polymerase chain reaction.
A
Fig. 1. Direct DNA sequence analysis of two patients with permanent neonatal diabetes revealed mutations of the KCNJ11 gene encod-
ing Kir6.2. Arrows indicate the nucleotide position affected by the mutation. Case 1 (A) had a nucleotide substitution with AAG to AGG at
position 509 in the exon 3. Case 2 (B) had a nucleotide substitution with GTG to ATG at position 175 in the exon 2.
Normal
GCTGCAT CTTCATGAAGACTGCCC AAGCCCAC
GCTGCAT CTTCATGANGACTGCCC AAGCCCAC
Patient
c.509 A>G
p.Lys170Arg (p.K170R) B
Normal
C TT CC TG C AGG AC G T G TTC ACCACGC T G
C TT CCTGC AGG ACN T G TTC ACCA CGC T G
Patient
c.175 G>A
p.Val59Met (p.V59M)618 M.S. Kim, S.-Y. Kim, G.-H. Kim, et al.
cutaneous tissue fluid within a range of 40-400 mg/dL. The
monitor records glucose levels every five minutes for 72 hr.
RESULTS
We identified two previously reported heterozygous muta-
tions (a a-to-g change at nucleotide 509, which resulted in a
lysine-to-arginine substitution at position 170 of the gene
encoding Kir6.2, K170R, in case 1, and a g-to-a change at
nucleotide 175, which resulted in a valine-to-methionine
substitution at position 59 in the gene encoding Kir6.2,
V59M, in case 2, Fig. 1).
In order to assess the pancreatic  -cell function, C-peptide
levels were measured in the patients with PND. On admis-
sion for glibenclamide therapy, C-peptide levels were 0.1 in
case 1 and 0.1 ng/mL in case 2 with corresponding blood
glucose levels of 119 and 400 mg/dL, respectively. The basal
levels of C-peptide levels, after one week of glibenclamide
treatment, were increased to more than 18 times higher than
the levels obtained during insulin therapy in case 1 and case
2 (Table 2). 
In order to compare the clinical response to glibenclamide
treatment with the response to the insulin therapy, frequent
capillary glucose measurement and CGMS were performed.
After seven days of glibenclamide treatment, no hyper- or hy-
poglycemic episode was observed in these patients. Fig. 2
shows three representative 24-hr glucose profiles obtained
by the CGMS in case 1. These patients remain well and off
insulin at 6 and 15 months of follow-up. 
DISCUSSION
Recently, it has been shown that PND can result from
mutations in Kir6.2 that reduce the ability for ATP to close
the ATP-sensitive K+ channel. We report here two differ-
ent heterozygous activating mutations of the KCNJ11 gene
in Korean children with PND.
PND is defined as hyperglycemia diagnosed within the
first three months of life and requires insulin therapy for life
(1). Although PND is a rare entity and the genetic etiology
is unknown in about half of affected patients, Kir6.2 muta- NA, not available.
Days after
sulfonylurea
Day 0
(Case 1/2)
Day 7
(Case 1/2)
Day 30
(Case 1/2)
Day 150
(Case 1/2)
1 yr
(Case 1/2)
Insulin NA/15.4 11.5/9.47 13.4/NA 10.4/15.8 NA/12.0
( IU/mL)
C-peptide 0.1/0.1 2.2/1.8 3.3/3.2 2.9/3.0 NA/2.0
(ng/mL)
Glucose 119/400 294/NA 150/NA 135/NA NA/NA
(mg/dL)
HbA1C 7.4/8.7 NA/NA 6.9/7.2 6.4/5.9 NA/5.8
Table 2. Serum insulin, C-peptide, and HbA1C levels after gliben-
clamide therapy 
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Fig. 2. A three representative 24-hr long recordings of glucose lev-
els at one day before glibenclamide therapy (insulin therapy only,
A) and one week (B) and one month (C) after glibenclamide the-
rapy (only glibenclamide therapy), performed by continuous glu-
cose monitoring system in case 1.  C
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tions are a common cause of PND. To date, at least 63 pati-
ents with activating mutations in Kir6.2 have been described
from Europe, the Middle East, Australia, and North and South
America, comprising 21 different mutations in 49 families
(8, 9). The majority of cases have been Caucasian, but muta-
tions have been found in other ethnic groups. However, there
has been only one report from Japan in Asia with PND caused
by a Kir6.2 mutation (10). The cases reported here are the
first cases of PND with Kir6.2 mutations identified in Korea.
We found two different mutations (V59M and K170R) in
the Korean patients with PND. The V59M mutation is one
of the most common mutations identified to date (8). How-
ever, the K170R mutation is rare, and only one case has been
reported. There is emerging evidence for a clear genotype-
phenotype relationship for Kir6.2 mutations. Most patients
with a mutation at R201, the most common mutation, have
nonremitting neonatal diabetes without neurological fea-
tures. However, patients with the V59M mutation have
developmental delay and features consistent with interme-
diate DEND (developmental delay, epilepsy, and neonatal
diabetes) syndrome (8). The phenotypic expressions of the
two patients presented here are similar to those reported in
cases previously (8, 9). Our patients did not have type 1 asso-
ciated antibodies and had low levels of C-peptide. One of
two patients had low birth weight. Moreover, this patient
was small for gestational age. Both exhibited severe hyper-
glycemia and the need for subsequent exogenous insulin
within three months of life. The patient with the K170R
mutation had only PND. By contrast, patients with the
V59M mutation have neurological features (developmental
delay and muscles weakness) in addition to diabetes.
All mutations studied to date produce a marked decrease
in the ability of ATP to block the KATP channels when ex-
pressed in the heterologous systems (11-13). This reduction
in ATP sensitivity causes the channel to open more fully at
physiologically relevant concentrations of ATP, leading to
an increase in the KATP current. In pancreatic  -cells, an
increase in KATP current will hyperpolarize the membrane,
suppressing electrical activity, Ca2+ influx, and insulin secre-
tion, and thereby causes diabetes (14). KATP channels that
are insensitive to ATP as a consequence of Kir6.2 mutations
can still be closed by sulfonylurea that bind to the SUR sub-
unit and directly close the channel (6). A number of patients
with Kir6.2 mutations have been able to discontinue their
insulin injections completely and obtain as good as, or bet-
ter glycemic control, using oral sulfonylurea (7, 15-17). In
our cases, we discontinued insulin injection and introduced
high dose oral glibenclamide therapy (0.8-0.9 mg/kg/day).
The continuous glucose monitoring systems were compara-
ble during and after insulin treatment, and the HbA1C lev-
els declined after insulin had been discontinued. However,
these patients still required high doses of sulfonylurea, com-
pared with adults with type 2 diabetes, as has been reported
in other studies (15-17). Mutations that affect the probability
of opening the channel are less sensitive to inhibition by sul-
fonylurea in vitro (13, 18). Therefore, even higher drug doses
may be necessary in patients with PND. To date, the longest
duration recorded in a patient has remained off insulin has
been about two years (8). Therefore, long-term follow-up
studies are now required to assess whether the response to
sulfonylurea is maintained, and whether sulfonylurea thera-
py is better than insulin therapy.
In conclusion, mutations in the gene KCNJ11 encoding
Kir6.2 can cause PND in Korean children, and oral sulfony-
lurea therapy is as good as, or better than glycemic control,
obtained with insulin therapy. All patients with PND should
be tested for KCNJ11 mutations for appropriate management
and follow-up.
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